1048 related articles for article (PubMed ID: 28779400)
21.
Wondergem M; van der Zant FM; Knol RJJ; Burgers AMG; Bos SD; de Jong IJ; Pruim J
World J Urol; 2018 Jan; 36(1):27-34. PubMed ID: 29043431
[TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of planar bone scintigraphy, SPECT, SPECT/CT, 18F-NaF PET/CT and whole body 1.5T MRI, including DWI, for the detection of bone metastases in high risk breast and prostate cancer patients: SKELETA clinical trial.
Jambor I; Kuisma A; Ramadan S; Huovinen R; Sandell M; Kajander S; Kemppainen J; Kauppila E; Auren J; Merisaari H; Saunavaara J; Noponen T; Minn H; Aronen HJ; Seppänen M
Acta Oncol; 2016; 55(1):59-67. PubMed ID: 25833330
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Bone Uptake in Bone Scan and Ga-68 PSMA PET/CT Images in Patients with Prostate Cancer.
Acar E; Bekiş R; Polack B
Curr Med Imaging Rev; 2019; 15(6):589-594. PubMed ID: 32008568
[TBL] [Abstract][Full Text] [Related]
24. 18F-Labeled NaF PET-CT in Detection of Bone Metastases in Patients With Preoperative Lung Cancer.
Rao L; Zong Z; Chen Z; Wang X; Shi X; Yi C; Zhang X
Medicine (Baltimore); 2016 Apr; 95(16):e3490. PubMed ID: 27100456
[TBL] [Abstract][Full Text] [Related]
25. Quantitative bone SPECT/CT: high specificity for identification of prostate cancer bone metastases.
Tabotta F; Jreige M; Schaefer N; Becce F; Prior JO; Nicod Lalonde M
BMC Musculoskelet Disord; 2019 Dec; 20(1):619. PubMed ID: 31878904
[TBL] [Abstract][Full Text] [Related]
26. Total-Body
Pomykala KL; Czernin J; Grogan TR; Armstrong WR; Williams J; Calais J
J Nucl Med; 2020 Mar; 61(3):405-411. PubMed ID: 31541035
[TBL] [Abstract][Full Text] [Related]
27. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
Robu S; Schottelius M; Eiber M; Maurer T; Gschwend J; Schwaiger M; Wester HJ
J Nucl Med; 2017 Feb; 58(2):235-242. PubMed ID: 27635024
[TBL] [Abstract][Full Text] [Related]
28. Application of [
Dadgar H; Emami F; Norouzbeigi N; Vafaee MS; Jafari E; Gholamrezanezhad A; Assadi M; Ahmadzadehfar H
Mol Imaging Biol; 2020 Aug; 22(4):1062-1069. PubMed ID: 31758511
[TBL] [Abstract][Full Text] [Related]
29. Efficacy, Predictive Factors, and Prediction Nomograms for
Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
[TBL] [Abstract][Full Text] [Related]
30. Prospective comparison of whole-body bone SPECT and sodium 18F-fluoride PET in the detection of bone metastases from breast cancer.
Abikhzer G; Srour S; Fried G; Drumea K; Kozlener E; Frenkel A; Israel O; Fogelman I; Kagna O
Nucl Med Commun; 2016 Nov; 37(11):1160-8. PubMed ID: 27536906
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
32. Is there a utility of adding skeletal imaging to 68-Ga-prostate-specific membrane antigen-PET/computed tomography in initial staging of patients with high-risk prostate cancer?
Raju S; Sharma A; Patel C; Sahoo R; Das CJ; Kumar S; Sharma A; Kumar R
Nucl Med Commun; 2020 Nov; 41(11):1183-1188. PubMed ID: 32796451
[TBL] [Abstract][Full Text] [Related]
33. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
34. Prospective comparison of
Zacho HD; Nielsen JB; Afshar-Oromieh A; Haberkorn U; deSouza N; De Paepe K; Dettmann K; Langkilde NC; Haarmark C; Fisker RV; Arp DT; Carl J; Jensen JB; Petersen LJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1884-1897. PubMed ID: 29876619
[TBL] [Abstract][Full Text] [Related]
35.
Dyrberg E; Hendel HW; Huynh THV; Klausen TW; Løgager VB; Madsen C; Pedersen EM; Pedersen M; Thomsen HS
Eur Radiol; 2019 Mar; 29(3):1221-1230. PubMed ID: 30132104
[TBL] [Abstract][Full Text] [Related]
36.
Maurer T; Robu S; Schottelius M; Schwamborn K; Rauscher I; van den Berg NS; van Leeuwen FWB; Haller B; Horn T; Heck MM; Gschwend JE; Schwaiger M; Wester HJ; Eiber M
Eur Urol; 2019 Apr; 75(4):659-666. PubMed ID: 29625755
[TBL] [Abstract][Full Text] [Related]
37. Eligibility for
Cook GJR; Wong WL; Sanghera B; Mangar S; Challapalli A; Bahl A; Bassett P; Leaning D; Schmidkonz C
J Nucl Med; 2023 Feb; 64(2):227-231. PubMed ID: 36302657
[No Abstract] [Full Text] [Related]
38. Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer.
Freitag MT; Radtke JP; Hadaschik BA; Kopp-Schneider A; Eder M; Kopka K; Haberkorn U; Roethke M; Schlemmer HP; Afshar-Oromieh A
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):70-83. PubMed ID: 26508290
[TBL] [Abstract][Full Text] [Related]
39. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
40. The Value of
Su HC; Zhu Y; Hu SL; Liu C; Lin GW; Dai B; Zhang YJ; Ye DW
Ann Surg Oncol; 2019 Feb; 26(2):653-659. PubMed ID: 30324468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
